Literature DB >> 29231270

Profiling and characterization of microRNAs responding to sodium butyrate treatment in A549 cells.

Xiaoqiang Xiao1, Yingjie Cao1, Haoyu Chen1.   

Abstract

Butyrate inhibits growth of lung cancer. However, the molecular mechanism is still unclear. Here we profiled miRNAs that responded to sodium butyrate(NaB) stimulation in A549 cells, a non-small cell lung cancer cell line, using microarray. We found 33 up-regulated microRNAs and 22 down-regulated microRNAs (log2 ≥1.5 folds, P-value <0.05). The expression of miR-3935, miR-574-3p, and miR-494-3p was confirmed by realtime qPCR. Then,we explored their potential targets of miR-3935 and miR-494-3p using long noncoding RNA(LncRNA) microarray. Using cell expressing negative microRNA as control, we found 103 up-regulated transcripts (including 69 mRNA and 34 LncRNA), and 36 down-regulated transcripts (including 34 mRNAs and 2 LncRNA), in miR-3935 over-expressing A549 cells; 128 up-regulated transcripts (121 mRNAs, 7 LncRNAs) and 180 down-regulated transcripts (169 mRNAs, 11 LncRNAs) in mir-494-3p, respectively (log2 Fold change ≥ 1 & P < 0.05). The expression of RNF115, NTRK3, SLC39A6, and USB1 was confirmed with qPCR. Immunoblotting was adopted to detect RNF115 expression in miR-3935 overexpressed A549 cells. Then, using a luciferase reporter assay system, we found that miR-3935 overexpression significantly decreased 3UTR of RNF115 mediated luciferase expression .In addition, we also observed that the proliferation and migration of A549 cells was obviously prevented by miR-3935 overexpression. Finally, we showed miR-3935 and miR-494-3p induced interferon stimulated gene 15(ISG15) expression through activating its promoter transcription. Together, we profiled microRNAs that responded to NaB treatment and characterized their biological functions in A549 cells. Those results provided new clue for the future treatment of non small cell lung cancer.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  RNF115; miR-3935; microarray; non small cell lung cancer; sodium butyrate

Mesh:

Substances:

Year:  2018        PMID: 29231270     DOI: 10.1002/jcb.26547

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  De- "bug"-ing the microbiome in lung cancer.

Authors:  Pakhi Birla; Fyza Y Shaikh
Journal:  Cancer Metastasis Rev       Date:  2022-05-19       Impact factor: 9.237

Review 2.  Multifaceted Roles of the E3 Ubiquitin Ligase RING Finger Protein 115 in Immunity and Diseases.

Authors:  Mei-Xia Wang; Tianzi Liuyu; Zhi-Dong Zhang
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 3.  The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases.

Authors:  Tingfeng Du; Aihua Lei; Naiyu Zhang; Cuiming Zhu
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

4.  Sodium butyrate-activated TRAF6-TXNIP pathway affects A549 cells proliferation and migration.

Authors:  Xiaoqiang Xiao; Yanxuan Xu; Haoyu Chen
Journal:  Cancer Med       Date:  2019-10-02       Impact factor: 4.452

Review 5.  Effects of Intestinal Microbial⁻Elaborated Butyrate on Oncogenic Signaling Pathways.

Authors:  Jiezhong Chen; Kong-Nan Zhao; Luis Vitetta
Journal:  Nutrients       Date:  2019-05-07       Impact factor: 5.717

Review 6.  The Role of Respiratory Microbiota in Lung Cancer.

Authors:  Dan Wang; Jingyi Cheng; Jia Zhang; Fangyu Zhou; Xiao He; Ying Shi; Yongguang Tao
Journal:  Int J Biol Sci       Date:  2021-08-25       Impact factor: 6.580

Review 7.  The role and mechanism of butyrate in the prevention and treatment of diabetic kidney disease.

Authors:  Xi Cheng; Tingting Zhou; Yanqiu He; Yumei Xie; Yong Xu; Wei Huang
Journal:  Front Microbiol       Date:  2022-08-09       Impact factor: 6.064

8.  Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis.

Authors:  Zhiyao Xu; Zhuha Zhou; Jing Zhang; Feichao Xuan; Mengjing Fan; Difan Zhou; Zhenyu Liuyang; Ximei Ma; Yiyang Hong; Yihong Wang; Sherven Sharma; Qinghua Dong; Guanyu Wang
Journal:  Acta Pharm Sin B       Date:  2020-11-28       Impact factor: 11.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.